Johnson & Johnson (JNJ) got hit with a $417 million verdict Monday in the first California trial evaluating an alleged link between the company's talcum powder products and ovarian cancer, Law360 reported.
The California jury set a new standard in the string of suits alleging J&J's talc products caused a woman's terminal cancer, setting a higher verdict amount than Missouri juries did.
After a four-week trial and two days of deliberation, the Los Angeles jury found Johnson & Johnson failed to warn plaintiff Eva Echeverria of the increased risk of ovarian cancer associated with use of the company's talcum products.
J&J stock traded slightly up 0.6% to $133.40 mid-afternoon Monday.
More of What's Trending on TheStreet:
